Cancer Research Targets Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adams, J.
Right arrow Articles by Banks, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adams, J.
Right arrow Articles by Banks, R. E.
[Cancer Research 60, 2898-2905, June 1, 2000]
© 2000 American Association for Cancer Research

Clinical Investigations

Vascular Endothelial Growth Factor (VEGF) in Breast Cancer: Comparison of Plasma, Serum, and Tissue VEGF and Microvessel Density and Effects of Tamoxifen1

Jacqueline Adams, Pauline J. Carder, Sarah Downey, Mary A. Forbes, Kenneth MacLennan, Victoria Allgar, Sarah Kaufman, Susan Hallam, Roy Bicknell, James J. Walker, Fiona Cairnduff, Peter J. Selby, Timothy J. Perren, Mark Lansdown and Rosamonde E. Banks2

Imperial Cancer Research Fund Cancer Medicine Research Unit [J. A., M. A. F., K. M., S. H., P. J. S., T. J. P., R. E. B.], Department of Pathology [P. J. C.], Breast Unit [S. D., M. L.], Department of Clinical Oncology [F. C.], Department of Research and Development [V. A.], and Department of Obstetrics and Gynaecology [S. K., J. J. W.], St James’s University Hospital, Leeds LS9 7TF; Imperial Cancer Research Fund Institute of Molecular Medicine Laboratories, University of Oxford, Oxford OX3 9DU [R. B.], United Kingdom

The assessment of angiogenesis in breast cancer is of importance as a key indicator of survival and response to therapy. Circulating vascular endothelial growth factor (VEGF) measurements may provide a less subjective analysis than microvessel density (MVD) or immunohistochemical analysis of VEGF expression; however, most studies have used serum, which is now known to largely reflect platelet-derived VEGF concentrations. This study examined for the first time both plasma (VEGFP) and serum (VEGFS) VEGF concentrations in 201 blood samples from pre- and postmenopausal healthy controls and from patients with benign breast disease, localized breast cancer, breast cancer in remission, or metastatic breast cancer and related these to other clinicopathological markers. VEGFP but not VEGFS concentrations of patients with localized disease were significantly elevated compared with normal controls (P = 0.016). Patients with metastatic disease had higher VEGFP and VEGFS levels than normal controls (P < 0.001, P = 0.044 respectively), and higher VEGFP, but not VEGFS, than patients with benign disease (P = 0.009) and patients with localized disease (P = 0.004). However, the highest VEGFP and VEGFS concentrations were seen in patients in remission compared with normal controls (P < 0.001 and P = 0.008, respectively). VEGFP concentrations in patients in remission were also higher than in patients with benign disease (P = 0.01) or patients with localized disease (P = 0.005). Tamoxifen treatment was significantly associated with higher circulating and platelet-derived VEGF levels. Circulating VEGF did not correlate with any clinicopathological factor, including MVD or VEGF expression. VEGF expression was significantly correlated with estrogen receptor status and inversely correlated with tumor grade. MVD correlated with tumor size. Tamoxifen-induced increases in VEGF may be important in clinical prognosis or associated pathologies.




This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
M. Joao Bugalho, D. Madureira, C. Espadinha, A. Paula Font, and L. G Sobrinho
Serum vascular endothelial growth factor levels in patients with medullary thyroid carcinoma
Eur. J. Endocrinol., August 1, 2008; 159(2): 167 - 169.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. E. Holmes, J. C. Huang, T. R. Pace, A. B. Howard, and H. B. Muss
Tamoxifen and Aromatase Inhibitors Differentially Affect Vascular Endothelial Growth Factor and Endostatin Levels in Women with Breast Cancer
Clin. Cancer Res., May 15, 2008; 14(10): 3070 - 3076.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Banerjee, S. Pancholi, R. A'Hern, Z. Ghazoui, I. E. Smith, M. Dowsett, and L.-A. Martin
The Effects of Neoadjuvant Anastrozole and Tamoxifen on Circulating Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor 1 in Breast Cancer
Clin. Cancer Res., May 1, 2008; 14(9): 2656 - 2663.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Cervi, T.-T. Yip, N. Bhattacharya, V. N. Podust, J. Peterson, A. Abou-Slaybi, G. N. Naumov, E. Bender, N. Almog, J. E. Italiano Jr, et al.
Platelet-associated PF-4 as a biomarker of early tumor growth
Blood, February 1, 2008; 111(3): 1201 - 1207.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. S. Rudge, J. Holash, D. Hylton, M. Russell, S. Jiang, R. Leidich, N. Papadopoulos, E. A. Pyles, A. Torri, S. J. Wiegand, et al.
Inaugural Article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade
PNAS, November 20, 2007; 104(47): 18363 - 18370.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
D. Manau, F. Fabregues, J. Penarrubia, M. Creus, F. Carmona, G. Casals, W. Jimenez, and J. Balasch
Vascular endothelial growth factor levels in serum and plasma from patients undergoing controlled ovarian hyperstimulation for IVF
Hum. Reprod., March 1, 2007; 22(3): 669 - 675.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. Srikiatkhachorn, C. Ajariyakhajorn, T. P. Endy, S. Kalayanarooj, D. H. Libraty, S. Green, F. A. Ennis, and A. L. Rothman
Virus-Induced Decline in Soluble Vascular Endothelial Growth Receptor 2 Is Associated with Plasma Leakage in Dengue Hemorrhagic Fever
J. Virol., February 15, 2007; 81(4): 1592 - 1600.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
S. Motl
Bevacizumab in combination chemotherapy for colorectal and other cancers
Am. J. Health Syst. Pharm., May 15, 2005; 62(10): 1021 - 1032.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. D. Miller, J. M. Trigo, C. Wheeler, A. Barge, J. Rowbottom, G. Sledge, and J. Baselga
A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer
Clin. Cancer Res., May 1, 2005; 11(9): 3369 - 3376.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Koster, J. H.J.M. van Krieken, M. A. MacKenzie, M. Schraders, G. F. Borm, J. A.W.M. van der Laak, W. Leenders, K. Hebeda, and J. M.M. Raemaekers
Increased Vascularization Predicts Favorable Outcome in Follicular Lymphoma
Clin. Cancer Res., January 1, 2005; 11(1): 154 - 161.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn
Vascular Endothelial Growth Factor and Angiogenesis
Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
W. H. Dragowska, C. Warburton, D. T.T. Yapp, A. I. Minchinton, Y. Hu, D. N. Waterhouse, K. Gelmon, K. Skov, J. Woo, D. Masin, et al.
HER-2/neu Overexpression Increases the Viable Hypoxic Cell Population within Solid Tumors without Causing Changes in Tumor Vascularization
Mol. Cancer Res., November 1, 2004; 2(11): 606 - 619.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Murdoch, A. Giannoudis, and C. E. Lewis
Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues
Blood, October 15, 2004; 104(8): 2224 - 2234.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
W. Tangkeangsirisin and G. Serrero
PC cell-derived growth factor (PCDGF/GP88, progranulin) stimulates migration, invasiveness and VEGF expression in breast cancer cells
Carcinogenesis, September 1, 2004; 25(9): 1587 - 1592.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. D Zondor and P. J Medina
Bevacizumab: An Angiogenesis Inhibitor with Efficacy in Colorectal and Other Malignancies
Ann. Pharmacother., July 1, 2004; 38(7): 1258 - 1264.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. F. Shariat, V. A. Anwuri, D. J. Lamb, N. V. Shah, T. M. Wheeler, and K. M. Slawin
Association of Preoperative Plasma Levels of Vascular Endothelial Growth Factor and Soluble Vascular Cell Adhesion Molecule-1 With Lymph Node Status and Biochemical Progression After Radical Prostatectomy
J. Clin. Oncol., May 1, 2004; 22(9): 1655 - 1663.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Garvin and C. Dabrosin
Tamoxifen Inhibits Secretion of Vascular Endothelial Growth Factor in Breast Cancer in Vivo
Cancer Res., December 15, 2003; 63(24): 8742 - 8748.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. M. W. Verheul and H. M. Pinedo
The Importance of Platelet Counts and Their Contents in Cancer
Clin. Cancer Res., August 1, 2003; 9(9): 3219 - 3221.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. E. Murphy, M. R. J. Lansdown, V. Speirs, and P. J. Carder
Correspondence re: K. Heer et al., Serum Vascular Endothelial Growth Factor in Breast Cancer: Its Relation with Cancer Type and Estrogen Receptor Status. Clin. Cancer Res., 7: 3491-3494, 2001.
Clin. Cancer Res., August 1, 2003; 9(9): 3514 - 3514.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Dabrosin
Variability of Vascular Endothelial Growth Factor in Normal Human Breast Tissue in Vivo during the Menstrual Cycle
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2695 - 2698.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. M. J. J. Berns, J. G. M. Klijn, M. P. Look, N. Grebenchtchikov, R. Vossen, H. Peters, A. Geurts-Moespot, H. Portengen, I. L. van Staveren, M. E. Meijer-van Gelder, et al.
Combined Vascular Endothelial Growth Factor and TP53 Status Predicts Poor Response to Tamoxifen Therapy in Estrogen Receptor-positive Advanced Breast Cancer
Clin. Cancer Res., April 1, 2003; 9(4): 1253 - 1258.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. F. Dvorak
Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy
J. Clin. Oncol., November 1, 2002; 20(21): 4368 - 4380.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Buteau-Lozano, M. Ancelin, B. Lardeux, J. Milanini, and M. Perrot-Applanat
Transcriptional Regulation of Vascular Endothelial Growth Factor by Estradiol and Tamoxifen in Breast Cancer Cells: A Complex Interplay between Estrogen Receptors {alpha} and {beta}
Cancer Res., September 1, 2002; 62(17): 4977 - 4984.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. M. Tuttle, M. Fleisher, G. L. Francis, and R. J. Robbins
Serum Vascular Endothelial Growth Factor Levels Are Elevated in Metastatic Differentiated Thyroid Cancer but Not Increased by Short-Term TSH Stimulation
J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1737 - 1742.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Colleoni, A. Rocca, M. T. Sandri, L. Zorzino, G. Masci, F. Nole, G. Peruzzotti, C. Robertson, L. Orlando, S. Cinieri, et al.
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels
Ann. Onc., January 19, 2002; 13(1): 73 - 80.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. Sezer, C. Jakob, K. Niemoller, R. T.P. Poon, S.-T. Fan, and J. Wong
Angiogenesis in Cancer
J. Clin. Oncol., July 1, 2001; 19(13): 3299 - 3301.
[Full Text]

Home page
 Cancer Res.Home page
J. A. Foekens, H. A. Peters, N. Grebenchtchikov, M. P. Look, M. E. Meijer-van Gelder, A. Geurts-Moespot, T. H. van der Kwast, C. G. J. Sweep, and J. G. M. Klijn
High Tumor Levels of Vascular Endothelial Growth Factor Predict Poor Response to Systemic Therapy in Advanced Breast Cancer
Cancer Res., July 1, 2001; 61(14): 5407 - 5414.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
W. Jelkmann
Pitfalls in the Measurement of Circulating Vascular Endothelial Growth Factor
Clin. Chem., April 1, 2001; 47(4): 617 - 623.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Takahashi, R. Kawanishi-Tabata, A. Haba, M. Tabata, Y. Haruta, H. Tsai, and B. K. Seon
Association of Serum Endoglin with Metastasis in Patients with Colorectal, Breast, and Other Solid Tumors, and SuppressiveEffect of Chemotherapy on the Serum Endoglin
Clin. Cancer Res., March 1, 2001; 7(3): 524 - 532.
[Abstract] [Full Text]

Home page
 Nucleic Acids ResHome page
T. Bakheet, M. Frevel, B. R. G. Williams, W. Greer, and K. S. A. Khabar
ARED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins
Nucleic Acids Res., January 1, 2001; 29(1): 246 - 254.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.